Trials / Recruiting
RecruitingNCT07449234
A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis
A Non-interventional, Multi-centric, Single Country Observational Study to Assess the Safety and Effectiveness of Guselkumab After Ustekinumab (Originator or Biosimilar) in Moderate to Severe Psoriasis Patients in Clinical Routine
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (estimated)
- Sponsor
- Janssen-Cilag Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the effectiveness and safety of guselkumab following a switch from ustekinumab or an ustekinumab biosimilar in participants with moderate to severe psoriasis, a chronic inflammatory skin disease characterized by erythematous, scaly plaques that may be associated with pain and pruritus, in routine clinical practice.
Conditions
Timeline
- Start date
- 2026-02-09
- Primary completion
- 2027-03-15
- Completion
- 2027-09-01
- First posted
- 2026-03-04
- Last updated
- 2026-04-13
Locations
1 site across 1 country: Austria
Source: ClinicalTrials.gov record NCT07449234. Inclusion in this directory is not an endorsement.